AstraZeneca Strengthens China Hand With Massive R&D Boost
This article was originally published in PharmAsia News
AstraZeneca, which unlike many of its multinational peers continues to show strong growth in China, is building on this with a large investment aimed at building capacity for the development and manufacture of pharmaceuticals in the region.
You may also be interested in...
As the Chinese government looks to promote 'made in China' innovation, AstraZeneca has established a joint venture called Dizal Pharmaceuticals in tandem with a well-financed and influential local fund.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.